Pulmatrix (PULM) EPS (Basic) (2013 - 2026)

Pulmatrix (PULM) posted EPS (Basic) of -$0.36 for Q1 2026, up 95.37% sequentially from -$7.87 in Q4 2025, and up 27.12% YoY from -$0.29 in Q1 2025.

Pulmatrix (PULM) EPS (Basic) (2013 - 2026) Analysis & Trends

Pulmatrix has reported EPS (Basic) for 14 years, with the latest figure at -$0.36 in Q1 2026.

Quarterly EPS (Basic) rose 27.12% year-over-year to -$0.36 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.89 (down 162.28% YoY) and the FY2025 annual result came in at -$9.0, down 229.5% from the prior year.
EPS (Basic) advanced to -$0.36 in Q1 2026 per PULM's latest filing, from -$7.87 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.0 in Q4 2023 and troughed at -$7.87 in Q4 2025.
A 5-year average of -$1.37 and a median of -$0.71 in 2024 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2023 and 2024: EPS (Basic) surged 99.96% in 2023, then sank 137589.35% in 2024.
Over 5 years, EPS (Basic) stood at -$1.38 in 2022, then soared by 99.96% to -$0.0 in 2023, then plunged by 88648.59% to -$0.51 in 2024, then slumped by 1429.38% to -$7.87 in 2025, then soared by 95.37% to -$0.36 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.36, -$7.87, and -$0.23 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.57 Bn	131.72 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	86.71 Bn	78.72 Bn	3.93 Bn	12.62
3	Argenx Se	65.44 Bn	60.25 Bn	1.37 Bn	7.59
4	Moderna	60.06 Bn	54.93 Bn	52.00 Mn	-1.96
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	31.89 Bn	28.58 Bn	992.69 Mn	1.23
7	BioNTech SE	28.11 Bn	9.72 Bn	668.28 Mn	-0.72
8	Insmed	27.59 Bn	26.43 Bn	358.27 Mn	-0.06
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	0.18
10	Pulmatrix	5.59 Mn	5.59 Mn	-	-0.29

Download Data